Biotech

  • A Chapter 11 bankruptcy court document, with a pen under the word "bankruptcy."
    Image attribution tooltip
    FuzzMartin via Getty Images
    Image attribution tooltip

    Flagship-backed Omega signals it’s headed toward bankruptcy

    Flagship’s Pioneering Medicines initiative could acquire Omega’s assets via a stalking horse bid, according to a regulatory filing.

    By • Feb. 4, 2025
  • A candlestick stock chart is seen out of focus against a background of $100 dollar bills in this composite stock image.
    Image attribution tooltip
    Honglouwawa via Getty Images
    Image attribution tooltip

    Shares of psychedelics biotech nearly double on depression data

    The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was fast and effective in a treatment-resistant depression trial.

    By • Feb. 3, 2025
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline➔
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

    By BioPharma Dive staff
  • bird flu avian influenza migration
    Image attribution tooltip
    David McNew via Getty Images
    Image attribution tooltip

    Drugmakers prep for bird flu outbreak, despite continued low risk

    While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak. 

    By Kelly Bilodeau • Feb. 3, 2025
  • A chinese flag blowing in the wind
    Image attribution tooltip

    Istock/blackred

    Image attribution tooltip
    Sponsored by Evaluate

    Is 2025 the Chinese Year of BioPharma?

    China is now a dealmaking hot spot for firms seeking next-generation innovation. What will 2025 hold?

    Feb. 3, 2025
  • A person holds two blue drug tablets in their left hand.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip
    Deep Dive

    A new, non-opioid pain drug is here. Getting it to patients could be agony.

    After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?

    By • Jan. 31, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb

    Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer look in Europe and Daiichi Sankyo is switching CEOs.

    By BioPharma Dive staff • Jan. 31, 2025
  • A sign spelling Nasdaq hangs on the side of a building while a pedestrian passes by.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Metsera, Maze secure combined $415 million in IPOs

    The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.

    By • Jan. 30, 2025
  • A bottle of Vertex Pharmaceuticals' new pain medicine Journavx.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research

    Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit patients’ ability to access it.

    By • Updated Jan. 30, 2025
  • 23andMe
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    23andMe considers a sale as cash runs low

    The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations and financial commitments.

    By Nick Paul Taylor • Jan. 30, 2025
  • A woman smiles for a photo taken inside a science laboratory
    Image attribution tooltip
    Permission granted by Cargo Therapeutics
    Image attribution tooltip

    Cargo to drop lead CAR-T therapy, lay off staff after study setback

    Safety concerns and disappointing results led Cargo to stop testing the treatment, cut 50% of its workforce and evaluate strategic alternatives.

    By • Jan. 30, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    BioAge drops obesity drug; Akero, 89bio cash in on MASH data

    BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff. 

    By BioPharma Dive staff • Jan. 29, 2025
  • A 3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Atalanta banks $97M to send RNAi drugs into the brain

    The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat conditions like Huntington’s.

    By • Jan. 28, 2025
  • A droplet from a pipette hangs over a series of test tubes in this stock image.
    Image attribution tooltip
    K-Kwanchai via Getty Images
    Image attribution tooltip
    Obesity drugs

    Versant invests again in obesity, this time backing Helicore Biopharma

    Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant in recent months.

    By • Jan. 28, 2025
  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Sage rebuffs Biogen bid to take it over

    Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to “maximize” shareholder value.

    By • Jan. 27, 2025
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip

    The biopharma industry outlook on 2025: Uncertainty and change

    The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats like competition from China.

    By • Jan. 24, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Mixed results for Keytruda; AbbVie to work with Neomorph

    Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and the FDA delayed a decision on Stealth’s Barth treatment.

    By BioPharma Dive staff • Jan. 24, 2025
  • Abstract financial graph with up trend line on neon light colour background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Ascentage prices first biotech IPO of 2025, raising $126M

    The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

    By • Jan. 23, 2025
  • Two people face each other and speak in a dark room in front of screens showing a black and white image of a lung.
    Image attribution tooltip
    Retrieved from Mass General Brigham on January 22, 2025
    Image attribution tooltip

    AI in medtech is taking off. Here are 4 trends to watch in 2025.

    New documents clarify how the FDA plans to regulate AI-enabled devices, experts say, but several important questions remain around insurance coverage and generative AI.

    By Elise Reuter • Jan. 23, 2025
  • A photo of BridgeBio Pharma CEO Neil Kumar
    Image attribution tooltip
    Permission granted by BridgeBio Pharma
    Image attribution tooltip
    Q&A

    BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors

    In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and Alnylam.

    By • Jan. 23, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Intellia makes progress on HAE study; 2 more China drug deals

    The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.

    By BioPharma Dive staff • Jan. 22, 2025
  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna gets $590M from US government for bird flu vaccine

    Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.

    By • Jan. 21, 2025
  • The Nasdaq Marketplace is seen on March 01, 2024 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Sionna, Odyssey join queue of biotechs testing investors’ IPO interest

    The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity in more than three months.

    By • Jan. 21, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs

    A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.

    By BioPharma Dive staff • Jan. 17, 2025
  • A view of Shanghai's skyline at dusk.
    Image attribution tooltip
    Nikida via Getty Images
    Image attribution tooltip
    Deep Dive // Emerging biotech

    ‘The bar has risen’: China’s biotech gains push US companies to adapt

    Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors and executives interviewed by BioPharma Dive.

    By • Jan. 16, 2025
  • An image for JPM2020 snippets articles
    Image attribution tooltip
    Danielle Ternes / BioPharma Dive
    Image attribution tooltip

    JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

    AbbVie's CEO hinted his company may be less willing to invest in psychiatry, while Lilly explained what it got wrong forecasting GLP-1 drug demand.

    By , , • Jan. 16, 2025